Toray obtains domestic rights for RNA therapeutic for idiopathic fibrosis from Bonac

Bonac Co., a Fukuoka-based startup with a focus on RNA therapeutics, has entered into an agreement with Toray to license for domestic use its drug candidate BNC-1021, an RNA for the treatment of idiopathic pulmonary fibrosis, to Toray who in turn has bought new Bonac shares.

Toray news release, January 6, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny